Applied Biotechnology Institute, Inc.
June 24, 2026
Theater 1
Type: Company Presentation
Focus Area:
Platform for Therapeutics
Applied Biotechnology Institute (ABI) has developed a protein production platform to address limitations found in cell culture systems. Conventional methods often require high-cost manufacturing, strict cold chain logistics, and administration via injection. The ABI platform utilizes maize grain as the recombinant host aided by proprietary technological improvements offering advantages of thermal stability, lower costs, and bioencapsulation enabling oral delivery. Candidates have been tested across multiple applications as industrial proteins and health products. Human and animal trials have been conducted on several vaccine candidates eliciting neutralizing antibodies and protection against their respective pathogens. Therapeutic proteins have also been tested including secretory IgA, which is difficult to manufacture in standard systems. The company has commercialized and out licensed industrial candidates and is now seeking partnerships for the pharmaceutical candidates.
Company HQ City:
San Luis Obispo
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2006
Lead Product in Development:
The lead human health product is a Hepatitis B oral Vaccine
TrypZean, an animal free-sourced trypsin, is the lead product that has been commercialized
Brazzein, a high intensity natural sweetener, is the lead product that is being out licnesed for commercialization
CEO
John Howard
Development Phase of Lead Product
Phase I
Number of Unlicensed Products Looking for Licensing
Seeking partners for several therapeutic and vaccine candidates which are at different stages in development.
When you expect your next catalyst update?
March 2027
What is your next catalyst (value inflection) update?
Completion of a Phase I human trial for the orally delivered hepatitis B vaccine
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}